Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$3.68 +1.9%	$3.57	$2.65 ▼ $11.00	$188.05M	-0.41	86,523 shs	31,379 shs
IMTX Immatics	$6.33 +7.3%	$6.03	$3.30 ▼ $13.09	$769.41M	0.93	766,925 shs	462,051 shs
MNMD Mind Medicine (MindMed)	$9.61 -1.1%	$8.26	$4.70 ▼ $10.49	$731.23M	2.49	1.51 million shs	819,084 shs
NRIX Nurix Therapeutics	$10.58 +0.2%	$11.70	$8.18 ▼ $29.56	$808.84M	2.14	866,742 shs	502,186 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	-0.28%	+1.12%	+2.85%	+4.64%	-33.76%
IMTX Immatics	-3.28%	-6.65%	-1.01%	+24.47%	-49.62%
MNMD Mind Medicine (MindMed)	-2.51%	-2.70%	+20.45%	+47.27%	+46.06%
NRIX Nurix Therapeutics	-0.09%	+4.87%	-13.09%	+10.46%	-51.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENGN enGene	3.3552 of 5 stars	3.5	5.0	1.8	2.5	0.6
IMTX Immatics	2.291 of 5 stars	3.6	3.0	1.7	1.7	0.0
MNMD Mind Medicine (MindMed)	2.5852 of 5 stars	3.6	3.0	2.3	0.8	0.6
NRIX Nurix Therapeutics	2.5724 of 5 stars	4.4	2.0	2.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENGN enGene	3.00	Buy	$23.29	532.76% Upside
IMTX Immatics	3.20	Buy	$14.67	131.70% Upside
MNMD Mind Medicine (MindMed)	3.22	Buy	$24.71	157.17% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	172.84% Upside

Current Analyst Ratings Breakdown

Latest ENGN, NRIX, IMTX, and MNMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	MNMD Mind Medicine (MindMed)	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$25.00
8/1/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENGN enGene	N/A	N/A	N/A	N/A	$5.35 per share	N/A
IMTX Immatics	$168.65M	4.56	$0.25 per share	24.97	$5.12 per share	1.24
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$2.44 per share	N/A
NRIX Nurix Therapeutics	$54.55M	14.83	N/A	N/A	$7.44 per share	1.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	9/10/2025 (Estimated)
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-59.29%	-15.54%	-12.11%	N/A
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.53	N/A	N/A	N/A	N/A	-50.24%	-39.41%	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)

Latest ENGN, NRIX, IMTX, and MNMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	Q3 2025	ENGN enGene	-$0.5084	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q1 2025	IMTX Immatics	-$0.38	-$0.66	-$0.28	-$0.66	$13.05 million	$6.48 million
7/31/2025	Q2 2025	MNMD Mind Medicine (MindMed)	-$0.38	-$0.50	-$0.12	-$0.50	N/A	N/A
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENGN enGene	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENGN enGene	0.09	12.66	12.66
IMTX Immatics	N/A	10.28	10.28
MNMD Mind Medicine (MindMed)	0.22	4.98	4.98
NRIX Nurix Therapeutics	N/A	6.82	6.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENGN enGene	64.16%
IMTX Immatics	64.41%
MNMD Mind Medicine (MindMed)	27.91%
NRIX Nurix Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ENGN enGene	10.40%
IMTX Immatics	3.30%
MNMD Mind Medicine (MindMed)	2.45%
NRIX Nurix Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENGN enGene	31	51.10 million	45.79 million	N/A
IMTX Immatics	260	121.55 million	117.54 million	Optionable
MNMD Mind Medicine (MindMed)	40	76.09 million	74.22 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable

ENGN, NRIX, IMTX, and MNMD Headlines

Recent News About These Companies

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 7.7% - Should You Buy?

4 hours ago | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Victory Capital Management Inc.

August 3, 2025 | marketbeat.com

Houte Hans Van Sells 5,402 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

August 2, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 5,402 Shares

August 2, 2025 | insidertrades.com

Oppenheimer Reiterates "Outperform" Rating for Nurix Therapeutics (NASDAQ:NRIX)

August 1, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,691.04 in Stock

July 31, 2025 | marketbeat.com

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,308 Shares

July 31, 2025 | marketbeat.com

6NRIX : 6 Analysts Assess Nurix Therapeutics: What You Need To Know

July 31, 2025 | benzinga.com

Houte Hans Van Sells 4,304 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

July 31, 2025 | insidertrades.com

Nurix Therapeutics (NASDAQ:NRIX) Shares Up 4.9% - Here's What Happened

July 29, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Invests $374,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 29, 2025 | marketbeat.com

ARK Investment Management LLC Has $18.90 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 27, 2025 | marketbeat.com

Nikko Asset Management Americas Inc. Decreases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 27, 2025 | marketbeat.com

New York State Common Retirement Fund Has $626,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 26, 2025 | marketbeat.com

Massachusetts Financial Services Co. MA Sells 24,398 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 22, 2025 | marketbeat.com

Nurix Therapeutics (NASDAQ:NRIX) Shares Down 5.4% - Here's What Happened

July 19, 2025 | marketbeat.com

Hussman Strategic Advisors Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

July 19, 2025 | marketbeat.com

Q3 EPS Forecast for Nurix Therapeutics Raised by Analyst

July 16, 2025 | marketbeat.com

Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright

July 15, 2025 | finance.yahoo.com

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

July 13, 2025 | seekingalpha.com

Nurix Therapeutics beats quarterly expectations on strong collaboration ...

July 11, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN, NRIX, IMTX, and MNMD Company Descriptions

enGene NASDAQ:ENGN

$3.68 +0.07 (+1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$3.70 +0.01 (+0.41%)

As of 04:10 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Immatics NASDAQ:IMTX

$6.33 +0.43 (+7.29%)

Closing price 04:00 PM Eastern

Extended Trading

$6.33 0.00 (0.00%)

As of 04:10 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Mind Medicine (MindMed) NASDAQ:MNMD

$9.61 -0.11 (-1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$9.61 0.00 (0.00%)

As of 06:28 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Nurix Therapeutics NASDAQ:NRIX

$10.58 +0.02 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$11.08 +0.51 (+4.77%)

As of 05:17 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time